- Home
- GXO vs RYTM Comparison
GXO vs RYTM Comparison
Compare GXO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GXO | RYTM |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GXO | RYTM |
|---|---|---|
| Price | $52.82 | $107.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $61.92 | ★ $128.31 |
| AVG Volume (30 Days) | ★ 1.0M | 974.2K |
| Earning Date | 02-11-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $12,921,000,000.00 | $174,334,000.00 |
| Revenue This Year | $13.37 | $47.34 |
| Revenue Next Year | $6.10 | $55.95 |
| P/E Ratio | $69.68 | ★ N/A |
| Revenue Growth | 16.94 | ★ 54.92 |
| 52 Week Low | $30.46 | $45.91 |
| 52 Week High | $57.99 | $122.20 |
Technical Indicators
Market Signals| Indicator | GXO | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 48.02 |
| Support Level | $53.37 | $106.00 |
| Resistance Level | $54.35 | $114.19 |
| Average True Range (ATR) | 1.06 | 4.98 |
| MACD | -0.04 | -0.58 |
| Stochastic Oscillator | 34.57 | 9.88 |
Price Performance
Historical ComparisonAbout GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.